We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

34 hedge funds and large institutions have $106M invested in Compass Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

24% more capital invested

Capital invested by funds: $85.4M → $106M (+$20.4M)

0% more funds holding

Funds holding: 34 → 34 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.46% less ownership

Funds ownership: 61.58% → 61.11% (-0.46%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
34
Holders Change
–
Holders Change %
0%
% of All Funds
0.57%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
6
Increased
6
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.62M
2
FCOMV
Foresite Capital Opportunity Management V
California
+$986K
3
O
OrbiMed
New York
+$690K
4
BlackRock
BlackRock
New York
+$355K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$334K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$4.12M
2
FCM
Farallon Capital Management
California
-$798K
3
RCM
RA Capital Management
Massachusetts
-$730K
4
CM
CM Management
Florida
-$586K
5
AI
Alphabet Inc
California
-$264K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$18.2M – – –
RSCM
2
Rock Springs Capital Management
Maryland
$14.1M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$11.7M +$4.62M +2,129,600 +94%
FCMV
4
Foresite Capital Management V
California
$11.7M – – –
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$8.8M +$334K +153,877 +5%
CA
6
CHI Advisors
New York
$7.5M – – –
APM
7
Avidity Partners Management
Texas
$5.3M – – –
VC
8
Vivo Capital
California
$5.3M – – –
CCM
9
Consonance Capital Management
New York
$4.22M -$4.12M -1,896,211 -54%
FCOMV
10
Foresite Capital Opportunity Management V
California
$4.12M +$986K +454,250 +41%
Blackstone Inc
11
Blackstone Inc
New York
$3.99M – – –
Vanguard Group
12
Vanguard Group
Pennsylvania
$3.98M -$154K -70,909 -5%
MIM
13
Monashee Investment Management
Massachusetts
$3.26M -$86.3K -39,770 -3%
FAM
14
Fred Alger Management
New York
$1.61M – – –
DCM
15
DAFNA Capital Management
California
$525K +$4.35K +2,003 +1%
BlackRock
16
BlackRock
New York
$433K +$355K +163,426 New
LP
17
LMR Partners
United Kingdom
$265K – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$175K +$115K +52,865 +397%
CM
19
CM Management
Florida
$80K -$586K -270,000 -90%
SIC
20
Salem Investment Counselors
North Carolina
$80K -$152K -70,000 -70%
Millennium Management
21
Millennium Management
New York
$74K -$23.2K -10,684 -28%
NCM
22
New Capital Management
Texas
$69K +$52.6K +24,243 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$65K – – –
Marshall Wace
24
Marshall Wace
United Kingdom
$63K +$51.5K +23,727 New
O
25
OrbiMed
New York
$58.2K +$690K +317,875 +1%
1
2

CMPX Hedge Fund Activity: Q2 2022 in Review

34 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2022, worth a combined $106M — up 24% from $85.4M a quarter earlier.

Fund positioning in CMPX was balanced in Q2 2022: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 8 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.62M. The largest seller was Consonance Capital Management, cutting an estimated $4.12M.

  • 34 institutional investors held Compass Therapeutics (CMPX) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $106M of Compass Therapeutics stock for Q2 2022, up 24% quarter-over-quarter.
  • 6 funds opened new Compass Therapeutics positions in Q2 2022 and 6 closed out, a net change of 0 holders.
  • The largest Compass Therapeutics buyer in Q2 2022 was Adage Capital Partners, an estimated $4.62M added.
  • The largest Compass Therapeutics seller in Q2 2022 was Consonance Capital Management, an estimated $4.12M sold.

Based on aggregated 13F filings for Q2 2022.